About The Book
Dr. Lars Sorenson has lost support for his dream of a cancer center.
Elijah-Co appears as a white knight, but with its own agenda.
Lars Sorenson, an ambitious young oncologist, is crushed when the promised funding for his cancer center is withdrawn. An obsessively secretive company, Elijah-Co, appears as a white knight—but with its own agenda. Lars can conduct human trials on Elijah-Co’s new cancer-killing drugs, but only if he agrees to perform a shadow study of one of them, EJ 181. Animal data suggests that this drug can reverse the aging process. Lars must prove its effectiveness in humans by conducting a clandestine trial. His research takes on greater urgency when he discovers that his wife’s mysterious illness may be cured by EJ 181. Half-truths and lies dot the landscape as Lars pursues Elijah-Co’s true goal of proving that EJ 181 can endow amortality.
Fiction is reality on steroids, and the novel Elijah-Co delivers that. Science fiction, however, needs to have deep roots in reality—the science must be believable. Dan Luedke’s experience with clinical cancer research provides the expertise for a credible scientific platform as Elijah-Co pursues age reversal and amortality.
About The Author
Dan W. Luedke is a retired medical oncologist and the author of numerous peer-reviewed articles. Dan’s post-retirement, part-time occupation is hospice medical director. He lives with his wife, Susan Luedke, a not-so-retired medical oncologist. They have two children and four grandchildren, who have chosen to live on opposite sides of the country. When they are not begging them to move back to St. Louis, Dan and Susan visit the kids and grandkids as often as possible. Elijah-Co is his first novel.
Indigo River Publishing (April 12, 2022)
Length: 272 pages